(Q36484561)

14 August 2017

1 reference

title

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? (English)

1 reference

14 August 2017

1 reference

Bahlis NJ

1

1 reference

14 August 2017

Lazarus HM

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

22 May 2006

1 reference

Bone Marrow Transplantation

14 August 2017

published in

1 reference

14 August 2017

volume

38

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

7-15

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705395

14 August 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Localized amyloidosis: a survey of 35 French cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Early genetic events provide the basis for a clinical classification of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Chromosomal abnormalities in systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

Primary systemic amyloidosis with delayed progression to multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Holter monitoring in AL amyloidosis: prognostic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Myeloma--new approaches to combined nephrological-haematological management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705395

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705395

1 reference

14 August 2017

1 reference